{{item.videoDuration}}
{{item.title}}
{{item.text}}
{{item.videoDuration}}
{{item.title}}
{{item.text}}
PwC Corporate Finance advises the shareholders of DCS Pharma AG (“DCS Pharma”, the “Company”) on the sale of the Company to IMCD N.V. (“IMCD”).
A team of PwC Switzerland led by Martin Frey, Partner Corporate Finance/ M&A, acted as lead advisor to the shareholders of DCS Pharma, the Swiss-based pharmaceutical distributor on the sale of the Company to IMCD.
DCS Pharma, headquartered in Basel, was founded in 2016 by the two Swiss pharmaceutical distributors Dolder AG and ChemSwiss AG and operates in eight markets including Spain, Italy, Germany, Mexico and China. In 2018, the Company generated revenues of CHF 68m with 64 employees. DCS Pharma’s product portfolio covers a range of active pharmaceutical ingredients for the pharmaceutical and nutraceutical industries.
IMCD, headquartered in Rotterdam, is a market leader in the sale, marketing and distribution of specialty chemicals and food ingredients and is listed on Euronext, Amsterdam. In 2018, IMCD generated revenues of EUR 2.4bn with more than 2,800 employees in over 47 countries.
In November, the parties signed an agreement to transfer 100% of the outstanding shares of DCS Pharma in two steps: 90% of the shares upon fulfilment of transaction-related conditions and the remaining 10% as per 31 December 2021. On 10 December 2019, the parties announced that IMCD completed the acquisition of 90% of the shares in DCS Pharma.
